Results 1 to 10 of about 124,823 (174)

Overexpression of CD86 enhances the ability of THP‐1 macrophages to defend against Talaromyces marneffei

Immunity, Inflammation and Disease, 2022
Background Macrophages are the first line of defense against Talaromyces marneffei. CD86 is a surface molecule expressed on antigen‐presenting cells, such as macrophages, that provide costimulatory signals necessary for T cell activation and survival. In
Rifeng Chen, Di Yang, Linxia Shen, Jinling Fang, Raqib Khan, Donghua Liu   +5 more
doaj   +2 more sources

Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma

Frontiers in Oncology, 2021
BackgroundCD86 has great potential to be a new target of immunotherapy by regulating cancer immune response. However, it remains unclear whether CD86 is a friend or foe in lower-grade glioma (LGG).MethodsThe prognostic value of CD86 expression in pan ...
Huaide Qiu, Huaide Qiu, Wei Tian, Yikang He, Yikang He, Jiahui Li, Chuan He, Yongqiang Li, Ning Liu, Jianan Li   +9 more
doaj   +2 more sources

The Ratio of CD86+/CD163+ Macrophages Predicts Postoperative Recurrence in Stage II-III Colorectal Cancer

Frontiers in Immunology, 2021
Tumor-associated macrophages (TAMs) are pivotal for tumor progression and metastasis. We investigated the stromal CD86+TAM/CD163+TAM (CD86/CD163) ratio as a novel prognostic biomarker for stage II-III colorectal cancer (CRC).
Guozeng Xu, Lei Jiang, Cheng Ye, Guizhen Qin, Zhanxiong Luo, Yuzhen Mo, Jian Chen   +6 more
doaj   +2 more sources

CD86+/CD206+ tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma [PDF]

PeerJ, 2020
Background As the main cellular ingredients of tumor microenvironment, tumor-associated macrophages (TAMs) play a vital role in tumor development and progression.
Dalong Sun, Tiancheng Luo, Pingping Dong, Ningping Zhang, Jing Chen, Shuncai Zhang, Longzi Liu, Ling Dong, Si Zhang   +8 more
doaj   +3 more sources

The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas

Epigenetics, 2020
CTLA-4 blocking therapeutic antibodies are currently under investigation in head and neck squamous cell carcinoma (HNSCC). A better understanding of the epigenetic regulation of the CD28 superfamily members CD28, CTLA-4, and ICOS and their B7 ligands ...
Luka de Vos, Ingela Grünwald, Emma Grace Bawden, Jörn Dietrich, Kathrin Scheckenbach, Constanze Wiek, Romina Zarbl, Friedrich Bootz, Jennifer Landsberg, Dimo Dietrich   +9 more
doaj   +2 more sources

CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4

Frontiers in Immunology, 2020
CD80 and CD86 are expressed on antigen presenting cells and are required to engage their shared receptor, CD28, for the costimulation of CD4 T cells. It is unclear why two stimulatory ligands with overlapping roles have evolved.
Neil Halliday, Neil Halliday, Cayman Williams, Alan Kennedy, Erin Waters, Anne M. Pesenacker, Blagoje Soskic, Claudia Hinze, Tie Zheng Hou, Behzad Rowshanravan, Daniel Janman, Lucy S. K. Walker, David M. Sansom   +12 more
doaj   +2 more sources

Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells

Arthritis Research & Therapy, 2020
Background Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) competes with CD28 for binding CD80/CD86 on antigen-presenting cells (APCs) to limit T cell activation.
Po-Chun Liu, Chih-Tai Ssu, Yen-Po Tsao, Teh-Ling Liou, Chang-Youh Tsai, Chung-Tei Chou, Ming-Han Chen, Chuen-Miin Leu   +7 more
doaj   +2 more sources

Tumor-associated macrophage expression in colorectal adenomas and carcinomas: relationship to Helicobacter pylori infection [PDF]

Frontiers in Oncology
ObjectiveThis study investigated the association between Helicobacter pylori (H. pylori) infection and the expression of CD163+ and CD86+ tumor-associated macrophages (TAMs) in colorectal adenoma (CRA) and colorectal cancer (CRC) tissues ...
Wenming Wang, Wenming Wang, Yueyong Zhu, Yunchao Zhu, Jin Wang   +4 more
doaj   +2 more sources

A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex

BMC Immunology, 2020
Background The use of anti-B cell based therapies in immune-mediated diseases targeting general B cell markers or molecules important for B cell function has increased the clinical needs of monitoring B cell subpopulations.
Susanne Axelsson, Anders Magnuson, Anna Lange, Aseel Alshamari, Elisabeth Hultgren Hörnquist, Olof Hultgren   +5 more
doaj   +2 more sources

CD86 regulates myeloma cell survival

Blood Advances, 2017
: Although prognosis for patients with multiple myeloma has improved over the past decade, research toward discovery of new therapeutic avenues is important and could lead to a cure for this plasma cell malignancy.
Catherine M. Gavile, Benjamin G. Barwick, Scott Newman, Paola Neri, Ajay K. Nooka, Sagar Lonial, Kelvin P. Lee, Lawrence H. Boise   +7 more
doaj   +2 more sources